Caris Life Sciences launched a $494 million IPO on Nasdaq, aiming to expand its molecular profiling assays and achieve profitability. The company leverages next-generation sequencing, AI, and machine learning to analyze over 6.5 million tests across nearly 850,000 cancer cases. Its comprehensive clinico-genomic database and assays—such as the FDA-approved MI Cancer Seek companion diagnostic—support precision oncology by identifying novel treatment options and partnering with biopharma firms including Moderna and Merck KGaA.